CBA Pharma 
Welcome,         Profile    Billing    Logout  
 1 Product   0 Diseases   1 Product   2 Trials   222 News 


1234567»
  • ||||||||||  CBT-1 (tetrandrine) / CBA Pharma
    Review, Journal:  Insights on exploring the therapeutic potential and structural modification of Tetrandrine. (Pubmed Central) -  Jan 6, 2025   
    This review systematically summarizes these modification strategies and evaluates the biological activities of Tet derivatives, aiming to guide further optimization and facilitate the discovery of lead analogs with improved efficacy. The future direction and possibility of Tet structural optimization are also considered.
  • ||||||||||  CBT-1 (tetrandrine) / CBA Pharma
    Journal:  Bis-benzylisoquinoline alkaloids inhibit flavivirus entry and replication by compromising endolysosomal trafficking and autophagy. (Pubmed Central) -  Dec 26, 2024   
    We evaluated five specific BBAs-berbamine, tetrandrine, iso-tetrandrine, fangchinoline, and cepharanthine-and found that they effectively inhibited infections by ZIKV, DENV, or JEV by blocking virus entry and genome replication stages in the flavivirus life cycle...Additionally, BBAs inhibited the fusion of autophagosomes and lysosomes, significantly reducing viral RNA replication. Collectively, our results suggest that BBAs inhibit flavivirus entry and replication by compromising endolysosomal trafficking and autophagy, respectively, underscoring the potential of BBAs as therapeutic agents against flavivirus infections.
  • ||||||||||  CBT-1 (tetrandrine) / CBA Pharma
    Journal:  Tetrandrine induces muscle atrophy involving ROS-mediated inhibition of Akt and FoxO3. (Pubmed Central) -  Nov 17, 2024   
    Mechanistically, Tet treatment caused ROS production in myotubes that in turn targeted on FoxO3/AKT signaling, resulting in the activation of UPS and autophagy processes that were involved in the protein degradation. Our study reveals a potential side-effect of Tet on skeletal muscle atrophy, particularly when the drug dose is relatively high.
  • ||||||||||  CBT-1 (tetrandrine) / CBA Pharma
    Preclinical, Journal:  Screening bioactive compounds from Fangji Huangqi Decoction for treating rheumatoid arthritis via COX-2 magnetic ligand fishing combined with in vivo validation. (Pubmed Central) -  Nov 13, 2024   
    The reason for these effects may be that tetrandrine can interact with the residue Tyr385 of COX-2, the enzymatic catalytic site of COX-2 to transform arachidonic acid (AA) to prostaglandin E2 (PGE2), and thereby reduce the production of prostaglandins and inflammatory metabolites. Moreover, in addition to tetrandrine, FHD contains other compounds that could supplement the activity of tetrandrine when FHD was used to treat RA, which is manifested the "multi-component" characteristic of how Traditional Chinese Medicine formulas treat diseases.
  • ||||||||||  CBT-1 (tetrandrine) / CBA Pharma
    Enrollment change, Trial withdrawal:  Tetrandrine Tablets Used in Hospitalized Adults With COVID-19 (clinicaltrials.gov) -  Sep 30, 2024   
    P4,  N=0, Withdrawn, 
    The biological effectiveness of these compounds was compared using the reference tetrandrine (IC50 N=414 --> 0 | Not yet recruiting --> Withdrawn
  • ||||||||||  CBT-1 (tetrandrine) / CBA Pharma
    Journal:  Development of Stephania tetrandra S. MOORE hairy root culture process for tetrandrine production. (Pubmed Central) -  Sep 14, 2024   
    The cultivation of hairy roots in a mist trickling bioreactor for eight weeks was less (26.24mg/L) than in the flask. Despite a lower tetrandrine yield observed in bioreactors compared to flask cultures, refining the growth medium and fine-tuning bioreactor operations hold promise for boosting tetrandrine yield.
  • ||||||||||  CBT-1 (tetrandrine) / CBA Pharma
    Journal:  Tetrandrine Activates STING/TBK1/IRF3 Pathway to Potentiate Anti-PD-1 Immunotherapy Efficacy in Non-Small Cell Lung Cancer. (Pubmed Central) -  Aug 24, 2024   
    We further revealed that the combination of TET with ?PD-1 monoclonal antibody (?PD-1 mAb) yields significant anti-cancer effects by promoting CD8+ T cell infiltration and enhancing its cell-killing effect, which in turn reduced the growth of tumors and prolonged survival of NSCLC mice. Therefore, TET effectively eliminates NSCLC cells and enhances immunotherapy efficacy through the activation of the STING pathway, and combining TET with anti-PD-1 immunotherapy deserves further exploration for applications.
  • ||||||||||  CBT-1 (tetrandrine) / CBA Pharma
    Journal:  Bis-benzylisoquinoline alkaloids inhibit African swine fever virus internalization and replication by impairing late endosomal/lysosomal function. (Pubmed Central) -  Aug 20, 2024   
    This study evaluated the anti-ASFV activities in porcine alveolar macrophages, 3D4/21 cells, and PK-15 cells of four bis-benzylisoquinoline alkaloids (BBAs): cepharanthine (CEP), tetrandrine, fangchinoline, and iso-tetrandrine...These collective results have profound implications for ASF prevention and control, suggesting the potential of the investigated agents as prophylactic and therapeutic measures. Furthermore, our study offers crucial insights into identifying drug targets and laying the groundwork for innovative interventions.
  • ||||||||||  CBT-1 (tetrandrine) / CBA Pharma
    Journal:  Structural basis for inhibition of the lysosomal two-pore channel TPC2 by a small molecule antagonist. (Pubmed Central) -  Aug 10, 2024   
    Here, we demonstrate that antagonist SG-094, a synthetic analog of the Chinese alkaloid medicine tetrandrine with increased potency and reduced toxicity, induces asymmetrical structural changes leading to a single binding pocket at only one intersubunit interface within the asymmetrical dimer...SG-094 arrests IIS4 in a downward shifted state which prevents pore opening via the IIS4/S5 linker, hence resembling gating modifiers of canonical VGICs. These findings may guide the rational development of new therapeutics antagonizing TPC2 activity.
  • ||||||||||  CBT-1 (tetrandrine) / CBA Pharma
    Review, Journal:  Advances in nano-preparations for improving tetrandrine solubility and bioavailability. (Pubmed Central) -  Jul 20, 2024   
    Great progress has been made in nanocarrier construction for TET delivery due to their outstanding advantages such as increased water-solubility, improved biodistribution and blood circulation, reduced off-target irritation, and combinational therapy. Herein, we systematically reviewed the latest advancements in TET-loaded nanoparticles and their respective features with the expectation of
  • ||||||||||  CBT-1 (tetrandrine) / CBA Pharma
    Journal:  Tetrandrine inhibits aldosterone synthesis by covalently targeting CYP11A1 to attenuate hypertension. (Pubmed Central) -  Jul 1, 2024   
    This study not only revealed the mechanism of the diuretic and antihypertensive effects of Tet but also discovered a novel covalent inhibitor of CYP11A1. These findings contribute significantly to our understanding of the therapeutic potential of Tet and provide a foundation for future research in the development of targeted treatments for hypertension.
  • ||||||||||  CBT-1 (tetrandrine) / CBA Pharma
    Journal:  The Role of Traditional Chinese Medicine in the Management of Cervical Cancer. (Pubmed Central) -  May 25, 2024   
    In recent years, the therapeutic effects and mechanisms of Chinese herbal medicines, such as the Guizhi-Fuling-decoction, the compound Yangshe granule, Huangqi, and Ginseng, herbal monomers (e.g., Ginsenoside Rh2, Tanshinone IIA, and Tetrandrine), and the related extracts and compound formulations, have received extensive attention for the treatment of cervical cancer...In addition, we reported a case of an advanced cervical cancer patient with multiple abdominal and pelvic metastasis who initially received chemotherapy, was then treated with TCM alone, and subsequently survived for 22 years. The model of whole-process management with TCM can enable more cancer patients to obtain longer survival periods.
  • ||||||||||  CBT-1 (tetrandrine) / CBA Pharma
    Journal:  Tetrandrine for Targeting Therapy Resistance in Cancer. (Pubmed Central) -  Mar 6, 2024   
    Recent work from our laboratory and others suggests that tetrandrine and its derivatives could be an excellent adjuvant to the current arsenal of anti-cancer drugs. Herein, we provide an overview of resistance mechanisms to current therapeutics and review the existing literature on the anti-cancer effects of tetrandrine and its potential use for overcoming therapy resistance in cancer.
  • ||||||||||  CBT-1 (tetrandrine) / CBA Pharma
    Design of Au-graphene quantum dot nanocomposite as a potential drug delivery system to solubilize Tetrandrine (Section 20) -  Mar 5, 2024 - Abstract #AACR2024AACR_7622;    
    The synthesis of nanocomposites (Au-GQD, Au-NGQD, Au-SGQD) and Tetrandrine-loaded products (AuGQD-T, AuNGQD-T, AuSGQD-T) will be examined. Additionally, the properties of Tetrandrine loaded onto the nanoparticles will be scrutinized and characterized using NMR spectroscopy, UV-Vis, and fluorescence spectrum analyses.
  • ||||||||||  CBT-1 (tetrandrine) / CBA Pharma
    Journal:  Protective effect of Tetrandrine on optic nerve by inhibiting glial activation through NF-?B pathway. (Pubmed Central) -  Feb 19, 2024   
    Moreover, LPS activate NF-?B signal pathway, while Tet efficiently inhibited this effect.Furthermore, injection of Tet did not damage theroutineblood, liver and kidney. Retrobulbar injection of Tet significantly alleviatedLPS-induced uveitisand optic nerve injuryof rats by activating gliocyte and NF-?B signaling pathway.
  • ||||||||||  CBT-1 (tetrandrine) / CBA Pharma
    Review, Journal:  Anti-Leukemic Attributes of Natural Compounds Targeting Autophagy: A (Pubmed Central) -  Feb 2, 2024   
    They have been shown to have synergistic effects with conventional chemotherapy, emphasizing their potential as supplementary medicines. However, additional research is required to fully comprehend their mechanisms of action and to maximize their role in clinical perspectives.
  • ||||||||||  CBT-1 (tetrandrine) / CBA Pharma
    Journal:  Borneol modified docetaxel plus tetrandrine micelles for treatment of drug-resistant brain glioma. (Pubmed Central) -  Jan 18, 2024   
    And we also found that targeting micelles could inhibit cell proliferation, promote cell apoptosis and inhibit the expression of drug-resistant protein, thus provide a new treatment method for GSCs in vitro and in vivo. BO modified DTX plus TET micelles may provide a new treatment method for drug-resistant brain gliomas.
  • ||||||||||  CBT-1 (tetrandrine) / CBA Pharma
    Journal:  Evaluating the Efficacy of Polyglycolic Acid-Loading Tetrandrine Nanoparticles in the Treatment of Dry Eye. (Pubmed Central) -  Dec 25, 2023   
    These findings offer a theoretical foundation for potential clinical application of TET therapy in patients with MI/RI. Tet-ATS@PLGA can effectively promote the apoptosis of inflammatory corneal epithelial cells, thus inhibiting the expression of inflammatory factors to block the formation of DED and improve the secretion of tear on the ocular surface.
  • ||||||||||  CBT-1 (tetrandrine) / CBA Pharma
    Trial completion date, Trial initiation date, Trial primary completion date:  Tetrandrine Tablets Used in Hospitalized Adults With COVID-19 (clinicaltrials.gov) -  Nov 18, 2023   
    P4,  N=414, Not yet recruiting, 
    Our findings identify a new combinatorial approach for treating KRAS-mutant PDAC and highlight the role of TRAIL-DR4/DR5 axis in dictating the therapeutic outcome in KRAS-mutant PDAC. Trial completion date: Dec 2024 --> Dec 2025 | Initiation date: Jan 2023 --> Dec 2023 | Trial primary completion date: Dec 2024 --> Dec 2025